secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001193125-25-245552
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 1.01, 3.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Neurosciences raises up to $200M to fund Phase 3 trial of roluperidone
------------------------------------------------------------------------------

- Private placement: $80M upfront Series A preferred; Tranche A warrants for another $80M (cash exercise), Tranche B warrants for $40M contingent on milestone event.
- Proceeds to finance Phase 3 confirmatory trial, NDA resubmission, and U.S. commercial launch readiness for roluperidone in negative symptoms of schizophrenia.
- Board to increase by up to three directors designated by Vivo Capital, expected to have schizophrenia trial experience.
- Closing expected October 23, 2025; led by Vivo Capital with participation from Janus Henderson, Farallon, and others.
- Company notes alignment with FDA on confirmatory trial design announced August 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312525245552/0001193125-25-245552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312525245552/d28380d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-245552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer